RBC Raises Ligand Pharmaceuticals Price Target to $357
RBC raised its price target on Ligand Pharmaceuticals to $357 from $345 and kept its Outperform rating.
RBC raised its price target on Ligand Pharmaceuticals to $357 from $345 and kept its Outperform rating.